Acute Lung Injury Market | Business Growth, Development Factors, Current and Future Trends till 2029

 For those planning market entry or expansion, this report lays out critical data and expert analysis on the acute lung injury industry landscape.

 

 Acute Lung Injury Market Analysis & Forecast: 2025–2029
 The acute lung injury market size has grown steadily in recent years. It will grow from $2.48 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to awareness campaigns, increase in ICU admissions, smoking and air pollution, hospital-acquired infections, and mortality rate reduction efforts.
 
 The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.07 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to biologics and gene therapies, government funding and grants, the development of precision medicine, regenerative medicine and stem cell therapies, and global health policy reforms. Major trends in the forecast period include development of biologic drugs, wearable and remote monitoring devices, inhalation-based therapies, CRISPR and gene editing technologies and biosensors for real-time analysis.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=20704&type=smp
 
 What Are The Factors Driving The Acute Lung Injury Market?
 The rising prevalence of respiratory diseases is expected to propel the growth of the acute lung injury market going forward. Respiratory diseases refer to a group of conditions that affect the lungs and other parts of the respiratory system, leading to difficulty in breathing and impaired lung function. The rising prevalence of respiratory diseases can be due to increased air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Respiratory diseases, such as pneumonia, cause acute lung injury by triggering severe inflammation and damaging the alveoli, leading to impaired gas exchange and respiratory distress. For instance, in September 2023, according to the Australian Bureau of Statistics, an Australia-based government agency, the death rate from influenza and pneumonia in the country rose from 31.9 per 100,000 people in 2021 to 42.6 per 100,000 people in 2022, reflecting a substantial increase of approximately 33.54%. Therefore, the rising prevalence of respiratory diseases is driving the growth of the acute lung injury market.
 
 What Segments Are Covered In The Acute Lung Injury Market Report?
 The acute lung injurymarket covered in this report is segmented — 
 
 1) By Injury Type: Direct Injury; Indirect Injury
 2) By Therapy: Mechanical Ventilation; Pharmacotherapy; Fluid Management; Other Therapies 
 3) By End User: Hospitals; Clinics; Other End Users
 
 Subsegments:
 1) By Direct Injury: Trauma-Induced Acute Lung Injury; Aspiration Pneumonitis; Pneumonia-Related Acute Lung Injury; Inhalation Injury 
 2) By Indirect Injury: Sepsis-Related Acute Lung Injury; Shock-Induced Acute Lung Injury; Acute Lung Injury Due To Blood Transfusion; Acute Lung Injury Associated With Pancreatitis 
 
 
 What Are The Main Trends, Positively Impacting The Growth Of Acute Lung Injury Market?
 Major companies operating in the acute lung injury market are focusing on developing novel treatments, such as peptide treatments, to sustain their position in the market. Peptide treatment refers to the use of short chains of amino acids (peptides) as therapeutic agents to treat medical conditions. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian-based healthcare company, launched Aviptadil for treating acute respiratory distress syndrome (ARDS). This treatment offers several unique benefits, including potent vasodilatory properties that are 50 times more effective than prostacyclin, a lung protection mechanism that promotes surfactant production by binding to alveolar type II cells, anti-inflammatory effects that inhibit pro-inflammatory cytokines like IL-6 and TNF-alpha, and immunomodulatory action to regulate immune responses in the lungs. Aviptadil has also shown clinical efficacy in improving outcomes for patients with severe viral-related ARDS.
 
 Which Are The Major Players Operating In The Global Acute Lung Injury Market?
 Major companies operating in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., MediciNova Inc. 
 
 View the full acute lung injury market report here:
 https://www.thebusinessresearchcompany.com/report/acute-lung-injury-global-market-report
 
 Acute Lung Injury Market Regional Insights:
 North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company